Citigroup
AUTL

Citigroup’s Autolus Therapeutics AUTL Stock Holding History

Citigroup’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.55K Sell
4,718
-888
-16% -$1.39K ﹤0.01% 5272
2026
Q1 		$7.74K Sell
5,606
-337
-6% -$512 ﹤0.01% 5136
2025
Q4 		$11.8K Buy
5,943
+2,086
+54% +$3.21K ﹤0.01% 5010
2025
Q3 		$6.29K Buy
3,857
+35
+0.9% +$68 ﹤0.01% 5168
2025
Q2 		$8.71K Buy
3,822
+659
+21% +$1.09K ﹤0.01% 5211
2025
Q1 		$4.9K Sell
3,163
-167
-5% -$339 ﹤0.01% 5272
2024
Q4 		$7.83K Sell
3,330
-214
-6% -$723 ﹤0.01% 5415
2024
Q3 		$12.9K Sell
3,544
-13,408
-79% -$53.5K ﹤0.01% 5251
2024
Q2 		$59K Sell
16,952
-65,633
-79% -$283K ﹤0.01% 4490
2024
Q1 		$527K Buy
82,585
+80,040
+3,145% +$499K ﹤0.01% 3532
2023
Q4 		$16.4K Buy
+2,545
New +$9.71K ﹤0.01% 5051
2023
Q1 		– Sell
-92
Closed -$175 – 5489
2022
Q4 		$175 Sell
92
-666
-88% -$1.68K ﹤0.01% 5608
2022
Q3 		$2K Sell
758
-199
-21% -$590 ﹤0.01% 5475
2022
Q2 		$3K Sell
957
-279
-23% -$849 ﹤0.01% 5761
2022
Q1 		$5K Sell
1,236
-509
-29% -$2.14K ﹤0.01% 5795
2021
Q4 		$9K Sell
1,745
-1,454
-45% -$8.73K ﹤0.01% 5575
2021
Q3 		$21K Sell
3,199
-72
-2% -$455 ﹤0.01% 5212
2021
Q2 		$22K Buy
3,271
+2,620
+402% +$16.3K ﹤0.01% 5237
2021
Q1 		$4K Sell
651
-366
-36% -$2.71K ﹤0.01% 5929
2020
Q4 		$9K Sell
1,017
-1,376
-58% -$14.7K ﹤0.01% 6974
2020
Q3 		$28K Sell
2,393
-132
-5% -$1.91K ﹤0.01% 5950
2020
Q2 		$40K Sell
2,525
-2,384
-49% -$26.4K ﹤0.01% 6154
2020
Q1 		$29K Buy
4,909
+2,868
+141% +$26.5K ﹤0.01% 6427
2019
Q4 		$27K Buy
2,041
+1,349
+195% +$17.7K ﹤0.01% 6768
2019
Q3 		$9K Buy
692
+228
+49% +$3.01K ﹤0.01% 7110
2019
Q2 		$7K Buy
464
+199
+75% +$4.45K ﹤0.01% 7381
2019
Q1 		$8K Buy
+265
New +$7.54K ﹤0.01% 7299

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citigroup's AUTL Position: Q2 2026 in Review

Citigroup reduced its Autolus Therapeutics (AUTL) stake by 16% in Q2 2026, selling an estimated $1.39K and leaving 4,718 shares worth $7.55K. The position accounts for ﹤0.01% of the portfolio, ranked #5272.

Citigroup first reported a position in AUTL in Q1 2019 and has held it in 27 quarters since. The position peaked at $527K in Q1 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Citigroup held 4,718 shares of Autolus Therapeutics worth $7.55K as of Q2 2026.
  • Citigroup sold 888 Autolus Therapeutics shares in Q2 2026, an estimated $1.39K.
  • Autolus Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5272 holding.
  • Citigroup first reported a position in Autolus Therapeutics in Q1 2019 and has held it in 27 quarters since.
  • Citigroup's Autolus Therapeutics position peaked at $527K in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.